(Q42861900)

8 November 2017

Progression of intramedullary metastasis during perioperative cessation of sunitinib (English)

1 reference

8 November 2017

Fausto Petrelli

1

1 reference

8 November 2017

Mary Cabiddu

2

1 reference

8 November 2017

Marinella Carpo

3

1 reference

8 November 2017

Mara Ghilardi

4

1 reference

8 November 2017

Sandro Barni

5

1 reference

8 November 2017

language of work or name

English

0 references

publication date

12 October 2010

1 reference

8 November 2017

Nature Reviews Urology

1 reference

8 November 2017

7

1 reference

8 November 2017

11

1 reference

8 November 2017

634-637

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2010.161

8 November 2017

0 references

cites work

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Surgical resection of renal cell carcinoma after targeted therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Sunitinib relieves renal cell carcinoma spinal cord compression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Brain metastases in patients with renal cell cancer receiving new targeted treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Complete cerebral response with sunitinib for metastatic renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Incidence of brain metastases in renal cell carcinoma treated with sorafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

A differential response to sunitinib: sustained systemic response paralleled by intra-dural progression in the spine. Should standard response criteria be reviewed?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2010.161

Sunitinib for treatment of advanced renal cell cancer: primary tumor response

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20938435

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Brain metastases. Histology, multiplicity, surgery, and survival

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20938435

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Brain metastasis in renal cell cancer responding to sunitinib.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20938435

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRUROL.2010.161

1 reference

8 November 2017

1 reference